Use of Nicergoline as Adjunctive Treatment of Neurotrophic Keratitis in Routine Clinical Practice: A Case Series.

Abstract

PURPOSE:

To describe the effectiveness and safety of nicergoline in patients with epithelial corneal defect or corneal ulcer due to neurotrophic keratitis (NK).

METHODS:

A prospective case series review was performed in 14 patients with NK who started treatment with nicergoline as an off-label prescription from January to November 2020. Patients with a epithelial defect or corneal ulcer due to NK were treated with oral nicergoline.

RESULTS/SERIAL CASES:

Complete corneal healing was observed in 10 (71.4%) of the 14 patients after 25.6 ± 26.60 days (range 7-90) with nicergoline. In three (21.5%) patients wound healing was not achieved, and one patient (7.1%) was lost to follow-up. The mean time between diagnosis and the starting of nicergoline was 10.92 ± 8.85 days (0-28). No adverse effects of nicergoline were observed.

CONCLUSION:

Nicergoline as an adjunctive treatment for NK showed a potential use in the healing of epithelial defect in real-life clinical practice.

• Authors: L Miguel-Escuder, C Rocha-de-Lossada, N Sabater-Cruz, José-María Sánchez-González, F Spencer, S Marín-Martínez, S Batlle-Ferrando, X Carreras Castañer, J Torras, J Peraza-Nieves
• Journal: Ocular immunology and inflammation (Ocul Immunol Inflamm) 2022 Oct-Nov Vol. 30 Issue 7-8 Pg. 1926-1930 ISSN: 1744-5078 [Electronic] England
• PMID: 34637676 (Publication Type: Journal Article)

Chemical References

• Nicergoline

Topics

• Humans
• Nicergoline
• Corneal Ulcer (diagnosis, drug therapy)